CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Vectibix for Left Sided Metastatic Colorectal Cancer – Details

Project Number PC0118-000
Brand Name Vectibix
Generic Name Panitumumab
Strength 20 mg/mL
Tumour Type Gastrointestinal
Indication Left Sided Metastatic Colorectal Cancer
Funding Request In combination with chemotherapy, for the first-line treatment of mCRC patients with left sided primary tumours that express wild-type RAS
Review Status Complete
Pre Noc Submission No
NOC Date August 31, 2015
Manufacturer Amgen Canada Inc.
Sponsor Amgen Canada Inc.
Submission Date September 8, 2017
Submission Deemed Complete September 15, 2017
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ September 22, 2017
Check-point meeting October 30, 2017
pERC Meeting January 18, 2018
Initial Recommendation Issued February 1, 2018
Feedback Deadline ‡ February 15, 2018
pERC Reconsideration Meeting March 15, 2018
Final Recommendation Issued March 29, 2018
Notification to Implement Issued April 16, 2018
Therapeutic Area Left Sided Metastatic Colorectal Cancer (mCRC)
Recommendation Type Do not reimburse

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.